Vaccinia virus protein

Vaccinia virus proteins constitute all protein products encoded by the vaccinia virus, the prototypic member of the orthopoxvirus genus in the family *Poxviridae*. The vaccinia genome encodes over 200 proteins, including structural proteins, enzymes (e.g., viral kinases like B1), immune modulators (such as those with Bcl-2–like folds), and replication/transcription machinery[2][4][6][8]. These proteins underlie the virus’s ability to infect host cells, evade immune responses, replicate, and assemble new virions. The extreme diversity of functions makes "Vaccinia virus proteins" too broad to serve as a canonical name or a conventional drug discovery target. Notably, some proteins have become the focus of cancer therapy by engineering vaccinia viruses as oncolytic agents, leveraging their ability to lyse cancer cells and stimulate anti-tumor immunity[1][3]. However, for therapeutic targeting and drug interaction, reference should be made to specific vaccinia virus proteins, not the proteome as a whole. In summary, "Vaccinia virus proteins" is an umbrella term for over 200 heterogeneous proteins with varied molecular functions within virus biology and engineered therapeutics, and does not define a single canonical drug target[2][6][8].

Other names

Vaccinia virus proteinsVACV proteinspoxvirus proteins

no unified mechanism; individual proteins may inhibit host immunity, serve as structural components, or enable viral replication